Clinical Trial Detail

NCT ID NCT02250326
Title Safety and Efficacy Study of Nab-Paclitaxel With CC-486 and Nab-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Celgene Corporation
Indications

non-small cell lung carcinoma

Therapies

Abraxane + Azacitidine

nab-paclitaxel

Age Groups: adult

No variant requirements are available.